Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Luye Pharma to Conduct $750 Million Hong Kong IPO

publication date: Feb 10, 2014
Luye Pharma is planning to stage a $750 million IPO in Hong Kong. Luye is a China company that makes TCM products, innovative drugs and biotech products. It is controlled by three China private equity companies, which bought a 77% stake in Luye in 2012 when the company had a market capitalization of $320 million. Later that year, the PE firms bought out the public shareholders and delisted Luye from the Singapore exchange. The new Hong Kong IPO is expected to value Luye at somewhere in the $1-$1.5 billion range. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital